Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Kurt A JaeckleJan C Buckner

Abstract

Oligodendroglioma frequently (> or = 70%) responds to radiation and chemotherapy, and is the first CNS neoplasm in which a genetic signature (1p and 19q deletion) has been associated with outcome within the context of large clinical trials. Current translational investigations focus on deletions or mutations of potential tumor suppressor genes, epigenetic alterations, amplification or mutation of growth factor and regulatory genes, and characterization of signaling events and regulatory protein expression. The most compelling data has involved 1p and 19q loss, which is observed in over 50% of anaplastic oligodendrogliomas. In two randomized phase III trials (Radiation Therapy Oncology Group 9402 and European Organisation for Research and Treatment of Cancer 26951), the addition of neoadjuvant or adjuvant procarbazine, lomustine, and vincristine (PCV; respectively) to radiotherapy did not produce superior survival as compared with radiotherapy alone. A modest increase in progression-free survival was observed with the addition of PCV, but at the cost of increased toxicity. Combined 1p and 19q loss identified a favorable prognostic group in both studies, which appeared to be independent of treatment arms. However, it is unclear w...Continue Reading

References

Apr 1, 1988·Annals of Neurology·J G Cairncross, D R Macdonald
Jul 1, 1996·Journal of Neuropathology and Experimental Neurology·J ReifenbergerG Reifenberger
Aug 1, 1997·Journal of Neuro-oncology·C Daumas-DuportJ P Chodkiewicz
Nov 5, 1997·Journal of Neuropathology and Experimental Neurology·D MaintzA von Deimling
Dec 17, 1997·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D SchifferC Bellotti
Oct 17, 1998·Journal of the National Cancer Institute·J G CairncrossD N Louis
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A JaeckleS C Schold
Oct 26, 1999·Journal of Neuro-oncology·B JeremicJ Aleksandrovic
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S SmithR B Jenkins
Jun 3, 2000·Journal of Neurology·J StrefferM Weller
Oct 6, 2000·International Journal of Radiation Oncology, Biology, Physics·G S BaumanJ G Cairncross
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O L ChinotF Grisoli
Jul 27, 2001·Neurology·M J van den BentA F Carpentier
Aug 7, 2001·Journal of Neuropathology and Experimental Neurology·S M DongH K Ng
Aug 22, 2001·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D FortinJ G Cairncross
Sep 12, 2001·Neuro-oncology·S H BignerR E McLendon
Jun 18, 2002·Acta Neurologica Scandinavica·J VaqueroS Coca
Sep 21, 2002·Journal of Neuro-oncology·Marc C Chamberlain
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan C BucknerRobert Jenkins
Jun 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kurt A JaeckleUNKNOWN North American Brain Tumor Consortium
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J van den BentUNKNOWN European Organization for Research and Treatment of Cancer Brain Tumor Group
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A A BrandesM Ermani
Dec 6, 2003·Oncology·Vinay K PuduvalliAthanassios P Kyritsis
Dec 23, 2003·Journal of Neuro-oncology·Lauren E AbreyJ Gregory Cairncross
Apr 22, 2004·Journal of Neuropathology and Experimental Neurology·Kenneth B FallonArie Perry
May 26, 2004·Neurology·C LebrunUNKNOWN Nice Brain Tumor Study Group
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Hoang-XuanJ Y Delattre
Sep 15, 2004·Neurology·V H J M TriebelsM J van den Bent
Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Maria MöllemannGuido Reifenberger
Mar 2, 2005·Acta Neuropathologica·Portia A KreigerJeffrey A Golden
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Jun 7, 2005·International Journal of Radiation Oncology, Biology, Physics·Stephanie E CombsJuergen Debus
Jun 14, 2005·Cancer Genetics and Cytogenetics·Mark E LawRobert B Jenkins
Jun 28, 2005·Neurological Research·Dan Ribom, Anja Smits

❮ Previous
Next ❯

Citations

Oct 13, 2006·Current Treatment Options in Oncology·Lyndon Kim, Michael Glantz
Jan 6, 2007·Nature Clinical Practice. Neurology·Mark R Gilbert, Frederick F Lang
Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StuppUNKNOWN ESMO Guidelines Working Group
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StuppUNKNOWN ESMO Guidelines Working Group
Nov 24, 2006·The Neurologist·Andrew D Norden, Patrick Y Wen
Feb 27, 2007·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Sejal ShahHoward T Chang
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matija SnuderlA John Iafrate
Apr 17, 2007·Neuro-oncology·Lauren E AbreyUNKNOWN Oligodendroglioma Study Group
Sep 16, 2011·Clinical Neurosurgery·Tiffany A Doucette, Ganesh Rao
Sep 8, 2010·Neurologic Clinics·Vikram C PrabhuJohn M Lee
Jul 12, 2008·Cancer Genetics and Cytogenetics·Kavita S Reddy
Apr 9, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Stephanie E CombsDaniela Schulz-Ertner
Feb 9, 2007·Cancer Letters·Jane Bayani, Jeremy A Squire
Dec 21, 2010·International Journal of Cancer. Journal International Du Cancer·Tiffany DoucetteGanesh Rao
May 24, 2015·Gene·Solmaz Khaghani-Razi-AbadElham Kazemi
Feb 1, 2015·International Journal of Radiation Oncology, Biology, Physics·Christina K SpeirsJiayi Huang
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederick F Lang, Mark R Gilbert
Jan 10, 2008·Expert Review of Anticancer Therapy·Isis Duran, Jeffrey J Raizer
Dec 9, 2008·The Cancer Journal·Gregory Cairncross, Robert Jenkins
Jun 9, 2006·Expert Review of Anticancer Therapy·Jennifer I Stern, Jeffrey J Raizer
May 27, 2009·Expert Opinion on Therapeutic Targets·Shoichi FumotoKeiko Hiyama
Jun 18, 2010·Journal of Neuro-oncology·François DucrayKhê Hoang-Xuan
Feb 8, 2007·International Journal of Cancer. Journal International Du Cancer·Detlef TrostRuthild G Weber
May 16, 2008·Journal of Neuro-oncology·Marc C Chamberlain, Michael J Glantz
Jan 18, 2019·JCO Clinical Cancer Informatics·Takuma ShibaharaYoshihiro Muragaki
Oct 1, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Bruno Marques CostaRui M Reis
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Iris LavonTali Siegal
Jul 1, 2008·Neuro-Chirurgie·M WagerL Karayan-Tapon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.